Lugano, Switzerland (ots/PRNewswire) - Temera, Luxochain and Polygon are pleased to announce their role as partners for the launch project of the new model Octo Finissimo Ultra, available in a limited edition of only 10 pieces. Bulgari with this initiative masters again its leadership as innovator in the hard luxury ...
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, promotes an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. An unmissable opportunity to look into this new sector of digital art, discover ...
Lugano, Switzerland and San Diego (ots/PRNewswire) - Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 Global Phase 3 study site recruitment is ongoing Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, ...
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
European Society for Medical Oncology (ESMO)
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
Woodcliff Lake, NJ, and Lugano, Switzerland (ots) - Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed- dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting ...
Lugano, Switzerland (ots) - Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S. subsidiary, Helsinn Therapeutics Inc. ("HTU"), effective 8 May 2014. Dr. Philip Schein was the former Founder, Chairman and CEO of US Biosciences, Inc., and Chair of the Clinical Investigations Committee of the National Cancer ...
Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational ...
Lugano, Switzerland - Beijing, PRC (ots) - Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United ...
Lugano, Switzerland (ots) - Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai ...
Lugano, Switzerland (ots) - The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi® (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The ...
MESA Medical Equipment Solutions and Applications
Lugano, Switzerland and Mikolow, Poland (ots) - Culminating from a three-year relationship involving operational synergies for diagnostic imaging service and equipment solutions, two of the largest multi-vendor service providers in Europe: Pan-European, Swiss-based Medical Equipment Solutions and Applications (MESA) ...
Lugano, Switzerland and Barcelona, Spain (ots) - The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or ...
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and ...
Lugano, Switzerland/Raleigh, N.C. (ots) - The Swiss pharmaceutical Helsinn Group, a leading player in the cancer supportive care arena, announced today that DARA BioSciences, Inc., a U.S. specialty pharmaceutical company focused on oncology and oncology supportive care products, has launched Gelclair® into the U.S. ...
Lugano, Switzerland (ots) - Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership development of women, to further the advancement and impact of women in healthcare worldwide. HBA accomplishes this by providing educational opportunities to develop cutting-edge industry ...
Lugano, Switzerland and Mexico City, Mexico (ots) - Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an innovative phase III ghrelin receptor agonist. Swiss pharmaceutical Helsinn Group has granted Latin American specialty ...
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
Lugano, Switzerland (ots) - ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which covered the whole spectrum of retinopathy, this year's meeting in the Czech Republic takes a significant step ...
Lugano, Switzerland and Melbourne, Australia (ots) - Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist Melbourne biopharmaceutical company Specialised Therapeutics ...